To include your compound in the COVID-19 Resource Center, submit it here.

Sphingomab: Phase Ib/IIa started

Lpath began the open-label, U.S. Phase Ib/IIa PEDigree trial to evaluate 0.5 and

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE